US FDA's cross-cutting Oncology “Center of Excellence” may be an efficient way to review new cancer treatments, but it is not a model that should be replicated for every therapeutic category across the agency, Office of New Drugs Director John Jenkins said during an exit-interview podcast ahead of his planned departure from the agency on Jan. 6.
“There is a lot of history behind how FDA is organized, and there is some rationale about how FDA is organized around products,” Jenkins said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?